Second malignant neoplasm risk after craniospinal irradiation in X-ray-based techniques compared to proton therapy.
Childhood malignancy
Craniospinal irradiation
EAR
IMRT
LAR
Proton therapy
Second malignancy
Tomotheraspy
VMAT
Journal
Australasian physical & engineering sciences in medicine
ISSN: 1879-5447
Titre abrégé: Australas Phys Eng Sci Med
Pays: Netherlands
ID NLM: 8208130
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
11
07
2018
accepted:
24
01
2019
pubmed:
7
2
2019
medline:
18
7
2019
entrez:
7
2
2019
Statut:
ppublish
Résumé
Cranio-spinal irradiation (CSI) is widely used for treating medulloblastoma cases in children. Radiation-induced second malignancy is of grave concern; especially in children due to their long-life expectancy and higher radiosensitivity of tissues at young age. Several techniques can be employed for CSI including 3DCRT, IMRT, VMAT and tomotherapy. However, these techniques are associated with higher risk of second malignancy due to the physical characteristics of photon irradiation which deliver moderately higher doses to normal tissues. On the other hand, proton beam therapy delivers substantially lesser dose to normal tissues due to the sharp dose fall off beyond Bragg peak compared to photon therapy. The aim of this work is to quantify the relative decrease in the risk with proton therapy compared to other photon treatments for CSI. Ten anonymized patient DICOM datasets treated previously were selected for this study. 3DCRT, IMRT, VMAT, tomotherapy and proton therapy with pencil beam scanning (PBS) plans were generated. The prescription dose was 36 Gy in 20 fractions. PBS was chosen due to substantially lesser neutron dose compared to passive scattering. The age of the patients ranged from 3 to 12 with a median age of eight with six male and four female patients. Commonly used linear and a mechanistic doseresponse models (DRM) were used for the analyses. Dose-volume histograms (DVH) were calculated for critical structures to calculate organ equivalent doses (OED) to obtain excess absolute risk (EAR), life-time attributable risk (LAR) and other risk relevant parameters. A α' value of 0.018 Gy
Identifiants
pubmed: 30725439
doi: 10.1007/s13246-019-00731-y
pii: 10.1007/s13246-019-00731-y
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM